- Home
- CRBP
as 05-30-2025 4:00pm EST
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | NORWOOD |
| Market Cap: | 73.4M | IPO Year: | N/A |
| Target Price: | $53.56 | AVG Volume (30 days): | 114.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.64 - $61.90 | Next Earning Date: | 05-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 150.00% |
Stock Insider Trading Activity of Corbus Pharmaceuticals Holdings Inc. (CRBP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Smethurst Dominic | CRBP | Chief Medical Officer | Mar 6 '25 | Sell | $6.78 | 6,393 | $43,329.84 | 70,807 |
Latest Corbus Pharmaceuticals Holdings Inc. News
CRBP Breaking Stock News: Dive into CRBP Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
MT Newswires
12 days ago
Mizuho Securities Adjusts Corbus Pharmaceuticals Price Target to $32 From $42, Maintains Outperform Rating
MT Newswires
12 days ago
Mizuho Cuts Price Target on Corbus Pharmaceuticals Holdings to $32 From $42, Keeps Outperform Rating
GlobeNewswire
13 days ago
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
GlobeNewswire
24 days ago
Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference
MT Newswires
25 days ago
RBC Cuts Price Target on Corbus Pharmaceuticals Holdings to $58 From $65, Keeps Outperform, Speculative Risk
Associated Press Finance
a month ago
Corbus Pharmaceuticals: Q1 Earnings Snapshot
GlobeNewswire
a month ago
Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Compare CRBP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRBP Corbus Pharmaceuticals Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.